In Today's episode of compounding lifestyle, we talk about AMC Shares Fall But The War Is Not Over, Market Recap from Last Week, Things to Look for This Week.



The Wallstreetbets stock AMC closed at $51.96 after falling almost 12% to $47.77 in morning trading after Iceberg's tweet that it had sold the shares short, which involves borrowing shares intending to buy them back at a lower price to cover the bet. AMC shares, while well below their June 2 peak of $72.62, were still up more than 2,500% year-to-date after finishing 2020 at $2.12. AMC's latest rally was helped by heavy trading of equity options, financial derivatives that give buyers the right to buy or sell shares at a fixed price in the future, depending on where the stock price is. As the share price skyrocketed, market makers who sold AMC options were forced to buy the company’s shares to offset their exposure, driving the stock higher in a phenomenon known as a gamma squeeze.



The Dow Jones set a record close while the S&P 500 and Nasdaq composite set all-time highs, all rising solidly for the week. The Russell 2000 retreated, as lenders fell modestly and some key growth stocks tumbled. That included EV makers Nio (NIO) and Xpeng (XPEV), but also shipping firms, China-related names, and many more. But Facebook, Microsoft (MSFT), and Google parent Alphabet (GOOGL) hit record highs, while Apple (AAPL) broke out of a base. The 10-year Treasury yield tumbled 11 basis points to 1.43%, the lowest since March. The U.S. economy added a stronger-than-expected 850,000 jobs in June, the best monthly gain since August, but the unemployment rate unexpectedly ticked up to 5.9%. Pockets of strong wage growth continued for sectors recovering from the pandemic. Average hourly pay jumped 2.3% over the prior month among nonsupervisory workers in the leisure and hospitality sector. That brought the 3-month pay to +6.2%. Facebook (FB) jumped to a record high in the stock market, and its market valuation topped $1trl for the 1st time after a U.S. District judge dismissed 2 antitrust lawsuits, one by the FTC and the other by a coalition of states alleging anti-competitive practices. Shares of CRISPR stocks popped on Monday after Intellia Therapeutics (NTLA) said its gene-editing approach to a liver disease showed promise in a Phase 1 test. Researchers tested a single dose of the drug in patients with a disorder caused by abnormal protein build-up. After 28 days patients showed a marked reduction in that protein. The news is important because it's the first time a company has tested a gene-editing drug inside humans, rather than on extracted cells before they're reinfused. In vivo gene-editing could be less expensive, easier to do, and more versatile. NTLA shot up about 85% for the week. Crispr Therapeutics (CRSP) gained more than 8% in the stock market.



$ARKX $XOM $TSLA $AAL $BNGO $MARA $O $CRWD $FB $AAPL $FCEL $MGM $GOOGL $EZGO $SHOP $MTCH $DIS $PDD $ $TWTR $AMZN $EBET $PLTR $BFLY $ENZC $GM $ABNB $BUZZ $PTON $TDOC $DDD $U BTC Eth, XLM

Control the Cash balance today and position yourself accordingly. Let's GO!!!!!


Research Links:
www.Finviz.com
www.Nasdaq.com



Learn more about options:
https://tinyurl.com/Compounding-Lifestyle

Music-Billions-Playglenthomas


Voice Mail link, show us some love, call in to ask questions: https://anchor.fm/compounding-lifestyle/message (copy/paste the URL)


CoinBase Link: https://www.coinbase.com/join/worthy_a7


Robinhood link: https://join.robinhood.com/arristw



DISCLAIMER: These Podcasts are for educational purposes only. Nothing in this podcast should be construed as financial advice or a recommendation to buy or sell any sort of security or investment. Consult with a professional financial advisor before making any financial decisions. Do your research and due diligence.